Walgreens (WAG) July Comps Rose 4.1%
Tweet
Share
E-mail
Walgreens (NYSE: WAG) had July sales rose 10.7% to $4,891,700,000. Comparable stores sales rose 4.1%, while comparable store front-end sales increased 4.2%.
July front-end sales were helped in part by strong sales of consumables and key beauty items. Zyrtec, which recently switched from prescription to over-the-counter status, benefited front-end sales by 0.4 percentage points. Meanwhile, front-end sales were hurt by promotional pricing in the photofinishing department and comparisons to last year's introduction of alli, the over-the-counter diet medication.
July pharmacy sales increased 10.8 percent, while comparable pharmacy sales increased 4.1 percent. Comparable pharmacy sales were negatively impacted by 2.1 percentage points due to generic drug introductions in the last 12 months.
July front-end sales were helped in part by strong sales of consumables and key beauty items. Zyrtec, which recently switched from prescription to over-the-counter status, benefited front-end sales by 0.4 percentage points. Meanwhile, front-end sales were hurt by promotional pricing in the photofinishing department and comparisons to last year's introduction of alli, the over-the-counter diet medication.
July pharmacy sales increased 10.8 percent, while comparable pharmacy sales increased 4.1 percent. Comparable pharmacy sales were negatively impacted by 2.1 percentage points due to generic drug introductions in the last 12 months.
You May Also Be Interested In
Create E-mail Alert Related Categories
Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
